1. Home
  2. INGN vs SPRO Comparison

INGN vs SPRO Comparison

Compare INGN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inogen Inc

INGN

Inogen Inc

HOLD

Current Price

$6.31

Market Cap

177.1M

Sector

Health Care

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.18

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INGN
SPRO
Founded
2001
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.1M
156.3M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
INGN
SPRO
Price
$6.31
$1.18
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$11.25
N/A
AVG Volume (30 Days)
195.1K
2.0M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
43.42
111.81
EPS
N/A
N/A
Revenue
$348,668,000.00
$66,802,000.00
Revenue This Year
$8.03
N/A
Revenue Next Year
$7.76
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
3.86
39.24
52 Week Low
$5.34
$1.08
52 Week High
$9.13
$3.08

Technical Indicators

Market Signals
Indicator
INGN
SPRO
Relative Strength Index (RSI) 48.07 20.75
Support Level $6.00 N/A
Resistance Level $6.73 $2.44
Average True Range (ATR) 0.24 0.16
MACD -0.03 -0.06
Stochastic Oscillator 41.79 9.13

Price Performance

Historical Comparison
INGN
SPRO

About INGN Inogen Inc

Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: